Goldman Sachs
IMMX icon

Goldman Sachs’s Immix Biopharma IMMX Stock Holding History

Goldman Sachs’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$869K Sell
95,404
-112,966
-54% -$830K ﹤0.01% 5189
2025
Q4 		$1.09M Buy
+208,370
New +$858K ﹤0.01% 5080

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Goldman Sachs's IMMX Position: Q1 2026 in Review

Goldman Sachs reduced its Immix Biopharma (IMMX) stake by 54% in Q1 2026, selling an estimated $830K and leaving 95,404 shares worth $869K. The position accounts for ﹤0.01% of the portfolio, ranked #5189.

Goldman Sachs first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.09M in Q4 2025. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Goldman Sachs held 95,404 shares of Immix Biopharma worth $869K as of Q1 2026.
  • Goldman Sachs sold 112,966 Immix Biopharma shares in Q1 2026, an estimated $830K.
  • Immix Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5189 holding.
  • Goldman Sachs first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • Goldman Sachs's Immix Biopharma position peaked at $1.09M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.